Mar 4, 2026 10:25am EST Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Mar 4, 2026 7:00am EST Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study